Investing.com - Impel Neuropharma reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Impel Neuropharma announced earnings per share of $-1.310 on revenue of $3.1M. Analysts polled by Investing.com anticipated EPS of $-1.000 on revenue of $5.81M.
Impel Neuropharma shares are down 67% from the beginning of the year, still down 66.84% from its 52 week high of $11.49 set on November 15, 2021.
Impel Neuropharma shares lost 0.52% in pre-market trade following the report.
Impel Neuropharma follows other major Healthcare sector earnings this month
Impel Neuropharma's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar